Odyssey Health Inc Stock Price, News & Analysis

Odyssey Health (OTC: ODYY) announced the dissolution of its sports advisory board aimed at concussion awareness to focus on its drug development efforts. The company has completed a Phase I trial of its concussion treatment drug, PRV-002, showing safety and tolerability. There are plans for a Phase II trial to assess efficacy in concussed patients. The company clarified that it has not received government funding and is not involved in litigation. Funding for the drug's development has come from accredited investors since acquiring the drug rights on March 1, 2021.

Odyssey Health (OTC: ODYY) has completed all cohorts of its Phase I clinical trial for PRV-002, a novel drug designed to treat concussion. Conducted on 40 healthy volunteers, the trial demonstrated that PRV-002 was safe and well tolerated, with no severe adverse events reported. The trial analyzed both Single Ascending Dosing (SAD) and Multiple Ascending Dosing (MAD) and showed a direct linear relationship between drug dosing concentration and plasma levels. Results indicate potential for greater delivery to the brain, supporting further clinical trials for concussion patients.

Odyssey Health, Inc. (OTC: ODYY) has successfully completed safety measures for the second cohort in its Phase I MAD clinical trial, testing PRV-002, a drug aimed at treating concussions. The trial involved 16 healthy subjects, with results showing that the drug was safe and well tolerated, with no severe adverse events reported. Odyssey is progressing towards its Phase II trial and is addressing a significant medical need as concussion treatment markets are projected to grow from $6.9 billion in 2020 to $8.9 billion by 2027.

Odyssey Health, Inc. (OTC: ODYY) has successfully completed safety measures for its Phase I Multi-Day Ascending Dosing (MAD) clinical trial of PRV-002, a novel drug designed to treat concussions. The first cohort involved eight healthy volunteers and reported no severe adverse events, indicating that the treatment was well-tolerated. The drug's pharmacokinetics demonstrated a direct linear relationship between dosing and blood levels, with significantly lower plasma levels noted for intranasal administration. The company is moving forward with the second cohort of the trial.

Odyssey Health (OTC: ODYY) announced positive safety results from Cohort I of its Phase I clinical trial for PRV-002, a drug addressing concussion treatment. Administered to eight healthy volunteers over five consecutive days, PRV-002 was found to be safe and well tolerated, with no severe adverse events reported. Conducted by Avance Clinical Pty Ltd, the trial aims to evaluate PRV-002's efficacy as a potential solution to a significant medical need in concussion management. The ongoing Phase I trial will include a total of 16 healthy subjects, with additional results to be reported.

Odyssey Health (OTC Pink: ODYY) is set to appear on Bloomberg TV's RedChip Money Report on July 16, 2022. The interview features spokesperson Brett Favre, discussing his personal concussion experiences and Odyssey's concussion treatment potential. The show reaches 73 million households, offering significant exposure for Odyssey. The company focuses on developing innovative medical solutions with a mission to enhance lives and ensure substantial returns for shareholders.

Odyssey Health (OTC Pink: ODYY) has successfully completed all three cohorts of its Phase I Single Ascending Dosing clinical trial for PRV-002, a novel concussion treatment. The drug was safe and well tolerated, showing promising pharmacokinetic results. The company plans to proceed with the Multiple Ascending Dosing phase and aims to meet with the FDA to discuss findings. The market for concussion treatments is projected to grow from $6.9 billion in 2020 to $8.9 billion by 2027, highlighting the potential impact of PRV-002 in addressing an unmet medical need.

Odyssey Health, Inc. (OTC Pink: ODYY) announced favorable safety results from Cohort II of its Phase I clinical trial for PRV-002, a novel drug to treat concussions. Conducted at Nucleus Network, this cohort included six healthy volunteers with no severe adverse events. All vital signs and blood tests remained normal, leading to unanimous approval for the next cohort with increased dosage. CEO Michael Redmond highlighted ongoing discussions for Phase II/III trials. The global concussion treatment market is projected to grow from $6.9 billion in 2020 to $8.9 billion by 2027.